Autolus Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Autolus Therapeutics (Nasdaq: AUTL) will participate in two investor events in March 2026. The company will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2028 at 11:10am EST / 4:10pm GMT, with CEO Dr. Christian Itin presenting and a webcast available. A replay will be archived for 90 days. Management will host investor meetings at Jefferies Biotech on the Beach Summit on March 10, 2026 in Miami, FL.
Positive
- None.
Negative
- None.
News Market Reaction – AUTL
In the Feb 24 session, AUTL gained 5.20%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.9% during that session. Argus tracked a trough of -4.7% from its starting point during tracking. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences.
TD Cowen 46th Annual Health Care Conference
Date and time: March 3, 2028; 11:10am EST / 4:10pm GMT
Location: Boston, MA
Presenter: Chief Executive Officer Dr. Christian Itin
A webcast of the presentation will be available on the “Events” page in the “Investor Relations & Media” section of the Company’s website at https://www.autolus.com/investor-relations-media/events/. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Jefferies Biotech on the Beach Summit
Management to host investor meetings
Date: March 10, 2026
Location: Miami, FL
About Autolus Therapeutics plc
Autolus Therapeutics plc (Nasdaq: AUTL) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit www.autolus.com.
Contact:
Amanda Cray
+1 617-967-0207
a.cray@autolus.com